3 stories from 2 sources
Day’s Recap is unavailable for this topic and date. Feel free to go through our curated list of stories below.
A curated list of other prominent stories from this day.
Confirmed Ebola cases in the Democratic Republic of Congo have risen to 782 as response teams in and around Goma confront deep mistrust from victims' relatives. Families are resisting treatment protocols and burial practices, complicating efforts to contain transmission.
4:23 PMAl JazeeraPeople who returned from prediabetes to normal blood sugar had a 58% lower risk of cardiovascular death or hospitalization for heart failure and a 42% lower risk of major cardiovascular events like heart attack or stroke. The risk reduction persisted for decades in long running cohorts in the U.S. and China.
8:50 AMScienceDailyFitbit data analysis found that after starting GLP-1 weight loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound, people logged fewer daily steps and less exercise even as they lost weight. The drop in activity raises concern because these drugs can reduce muscle mass as well as fat.
2:28 AMScienceDailySummary
Confirmed Ebola cases in the Democratic Republic of Congo have risen to 782 as response teams in and around Goma confront deep mistrust from victims' relatives. Families are resisting treatment protocols and burial practices, complicating efforts to contain transmission.
Why it matters
If social rejection of public health measures persists, the outbreak can outpace response operations and increase the odds of wider regional spread.
Summary
People who returned from prediabetes to normal blood sugar had a 58% lower risk of cardiovascular death or hospitalization for heart failure and a 42% lower risk of major cardiovascular events like heart attack or stroke. The risk reduction persisted for decades in long running cohorts in the U.S. and China.
Why it matters
If durable prediabetes reversal is achievable at scale, it could cut heart failure and major cardiac events faster and cheaper than waiting to treat diabetes and its complications.
Summary
Fitbit data analysis found that after starting GLP-1 weight loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound, people logged fewer daily steps and less exercise even as they lost weight. The drop in activity raises concern because these drugs can reduce muscle mass as well as fat.
Why it matters
If GLP-1 users lose weight but also lose movement and muscle, the long-term cardiometabolic and functional gains from these drugs could be smaller than expected.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!